📊 ARVN Key Takeaways
Is Arvinas, Inc.. (ARVN) a Good Investment?
Arvinas is a pre-commercial pharmaceutical company burning substantial cash with negative operating margins of -45.1% and free cash flow of -275.7M annually. While the company maintains adequate liquidity with $142.9M in cash and a strong current ratio of 4.92x, the accelerating cash burn rate and lack of meaningful revenue growth (-0.3% YoY) indicate an unsustainable operational model that will require additional financing or significant revenue inflection to survive beyond 2-3 years.
Arvinas shows mixed fundamentals: revenue is essentially flat, but net loss and diluted EPS improved materially year over year, indicating better operating efficiency and non-cash or partnership-related support. The balance sheet is strong with high liquidity and minimal debt, but the business still posts deeply negative operating margins and very weak free cash flow, so the core fundamental case depends on whether it can convert pipeline progress into more durable revenue and lower cash burn.
Why Buy Arvinas, Inc.. Stock? ARVN Key Strengths
- Strong liquidity position with $142.9M cash and 4.92x current ratio provides runway for operations
- Improving net income trend with 59.4% YoY improvement in net loss suggests operational efficiency gains
- Minimal debt burden with only $600K in long-term debt and 0.00x debt-to-equity ratio reduces financial risk
- Very strong liquidity with a 4.92x current and quick ratio
- Minimal leverage with only $0.6M of long-term debt against $433.9M of equity
- Net income loss narrowed significantly year over year, showing improving bottom-line trend
ARVN Stock Risks: Arvinas, Inc.. Investment Risks
- Massive negative free cash flow of -275.7M annually at 105% of revenue indicates unsustainable burn rate
- Stagnant revenue growth of -0.3% YoY with -45.1% operating margin demonstrates business model is not yet viable
- Operating cash burn of -273.8M exceeds cash reserves and will require significant external financing within 1-2 years
- Clinical stage company with no evidence of path to profitability or material revenue acceleration in near term
- Operating model remains unprofitable with a -45.1% operating margin
- Free cash flow is deeply negative at -$275.7M, indicating substantial ongoing cash burn
- Revenue declined slightly year over year, raising concern about growth durability and quality
Key Metrics to Watch
- Operating cash flow trend and runway to profitability based on current burn rate
- Revenue growth rate acceleration from new product approvals or clinical trial successes
- Gross margin achievement once products reach scale to offset R&D and operating expenses
- Operating cash burn and free cash flow trend
- Revenue growth quality and operating margin improvement
Arvinas, Inc.. (ARVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.92x current ratio provides a solid financial cushion.
ARVN Profit Margin, ROE & Profitability Analysis
ARVN vs Healthcare Sector: How Arvinas, Inc.. Compares
How Arvinas, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arvinas, Inc.. Stock Overvalued? ARVN Valuation Analysis 2026
Based on fundamental analysis, Arvinas, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arvinas, Inc.. Balance Sheet: ARVN Debt, Cash & Liquidity
ARVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arvinas, Inc..'s revenue has grown significantly by 227% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.62 indicates the company is currently unprofitable.
ARVN Revenue Growth, EPS Growth & YoY Performance
ARVN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $41.9M | -$13.4M | $-0.18 |
| Q2 2025 | $22.4M | $21.7M | $0.30 |
| Q1 2025 | $25.3M | -$69.4M | $-0.97 |
| Q3 2024 | $34.6M | -$49.2M | $-0.68 |
| Q2 2024 | $54.5M | -$35.2M | $-0.49 |
| Q1 2024 | $25.3M | -$69.4M | $-0.97 |
| Q3 2023 | $33.2M | -$64.0M | $-1.18 |
| Q2 2023 | $33.8M | -$66.6M | $-1.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arvinas, Inc.. Dividends, Buybacks & Capital Allocation
ARVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arvinas, Inc.. (CIK: 0001655759)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARVN
What is the AI rating for ARVN?
Arvinas, Inc.. (ARVN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARVN's key strengths?
Claude: Strong liquidity position with $142.9M cash and 4.92x current ratio provides runway for operations. Improving net income trend with 59.4% YoY improvement in net loss suggests operational efficiency gains. ChatGPT: Very strong liquidity with a 4.92x current and quick ratio. Minimal leverage with only $0.6M of long-term debt against $433.9M of equity.
What are the risks of investing in ARVN?
Claude: Massive negative free cash flow of -275.7M annually at 105% of revenue indicates unsustainable burn rate. Stagnant revenue growth of -0.3% YoY with -45.1% operating margin demonstrates business model is not yet viable. ChatGPT: Operating model remains unprofitable with a -45.1% operating margin. Free cash flow is deeply negative at -$275.7M, indicating substantial ongoing cash burn.
What is ARVN's revenue and growth?
Arvinas, Inc.. reported revenue of $262.6M.
Does ARVN pay dividends?
Arvinas, Inc.. does not currently pay dividends.
Where can I find ARVN SEC filings?
Official SEC filings for Arvinas, Inc.. (CIK: 0001655759) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARVN's EPS?
Arvinas, Inc.. has a diluted EPS of $-1.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ARVN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Arvinas, Inc.. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ARVN stock overvalued or undervalued?
Valuation metrics for ARVN: ROE of -18.6% (sector avg: 15%), net margin of -30.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ARVN stock in 2026?
Our dual AI analysis gives Arvinas, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARVN's free cash flow?
Arvinas, Inc..'s operating cash flow is $-273.8M, with capital expenditures of $1.9M. FCF margin is -105.0%.
How does ARVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30.8% (avg: 12%), ROE -18.6% (avg: 15%), current ratio 4.92 (avg: 2).